Teva Pharmaceutical Industries (TEVA) Revenue (2009 - 2026)
Teva Pharmaceutical Industries' (TEVA) quarterly Revenue came in at $4.1 billion in Q2 2026, down 0.81% YoY from $4.2 billion in Q2 2025, and up 4.02% on a QoQ basis from $4.0 billion in Q1 2026.
Teva Pharmaceutical Industries (TEVA) Revenue (2009 - 2026) Analysis & Trends
Teva Pharmaceutical Industries (TEVA) has 18 years of Revenue data on file, last reported at $4.1 billion in Q2 2026.
- Quarterly Revenue fell 0.81% year-over-year to $4.1 billion in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $17.3 billion (up 13.18% YoY) and the FY2025 annual result came in at $17.3 billion, up 4.32% from the prior year.
- Revenue advanced to $4.1 billion in Q2 2026, from $4.0 billion in the prior quarter.
- In the past five years, Revenue ranged from a high of $4.7 billion in Q4 2025 to a low of $2.9 billion in Q4 2024.
- A 5-year average of $4.0 billion and a median of $3.9 billion in 2022 frame the typical range for Revenue.
- Annual changes were most pronounced in 2024 — Revenue plunged 34.93% — and 2025, when it jumped 62.45%.
- Tracing TEVA's Revenue over 5 years: stood at $3.9 billion in 2022, then rose by 14.75% to $4.5 billion in 2023, then sank by 34.93% to $2.9 billion in 2024, then surged by 62.45% to $4.7 billion in 2025, then declined by 12.08% to $4.1 billion in 2026.
- The last three Revenue figures came in at $4.1 billion (Q2 2026), $4.0 billion (Q1 2026), and $4.7 billion (Q4 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 86.50 Bn | 85.53 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 42.71 Bn | 39.05 Bn | 2.15 Bn | 4.14 Bn |
| 3 | Zoetis | 30.86 Bn | 29.18 Bn | 1.80 Bn | 2.47 Bn |
| 4 | Takeda Pharmaceutical | 28.50 Bn | 22.70 Bn | 5.10 Bn | 7.65 Bn |
| 5 | United Therapeutics | 22.06 Bn | 19.40 Bn | 683.80 Mn | 783.30 Mn |
| 6 | Viatris | 18.84 Bn | 17.95 Bn | 1.46 Bn | 3.76 Bn |
| 7 | Neurocrine Biosciences | 15.55 Bn | 15.16 Bn | 935.80 Mn | 959.00 Mn |
| 8 | Vireo Growth | 11.86 Bn | 11.71 Bn | 59.30 Mn | 106.20 Mn |
| 9 | Elanco Animal Health | 11.77 Bn | 11.24 Bn | 798.00 Mn | 1.37 Bn |
| 10 | HUTCHMED (China) | 10.92 Bn | 9.54 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 4.14 Bn |
| Mar 31, 2026 | 3.98 Bn |
| Dec 31, 2025 | 4.71 Bn |
| Sep 30, 2025 | 4.48 Bn |
| Jun 30, 2025 | 4.18 Bn |
| Mar 31, 2025 | 3.89 Bn |
| Dec 31, 2024 | 2.90 Bn |
| Sep 30, 2024 | 4.33 Bn |
| Jun 30, 2024 | 4.16 Bn |
| Mar 31, 2024 | 3.82 Bn |
| Dec 31, 2023 | 4.46 Bn |
| Sep 30, 2023 | 3.85 Bn |
| Jun 30, 2023 | 3.88 Bn |
| Mar 31, 2023 | 3.66 Bn |
| Dec 31, 2022 | 3.88 Bn |
| Sep 30, 2022 | 3.60 Bn |
| Jun 30, 2022 | 3.79 Bn |
| Mar 31, 2022 | 3.66 Bn |
| Dec 31, 2021 | 4.10 Bn |
| Sep 30, 2021 | 3.89 Bn |